NCT01923363 - PK/PD of High Dose Pip/Tazo in Obese Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2014

Primary Completion Date

January 23, 2016

Study Completion Date

January 23, 2016

Conditions

Obesity

Interventions

DRUG

Piperacillin/Tazobactam Standard Dose to High Dose

Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.

Trial Locations (1)

92350

Loma Linda University Medical Center, Loma Linda

All Listed Sponsors

lead

Loma Linda University

OTHER